Autolus

Company snapshot

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving

• 1 approved product(s) across US/EU regulatory metadata.
• 16 active pipeline program(s) linked via ClinicalTrials.gov.
• 49 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Autolus. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Autolus.

1. Jun 8, 2026 Clinical update

   Genoxal polvo para solución inyectable y para... — Phase 2

2. Jun 8, 2026 Clinical update

   AUTO1-SL1 — Phase 1

3. Jun 8, 2026 Clinical update

   AUTO1-SL2 — Phase 2

4. Jun 8, 2026 Clinical update

   AUTO1-MS1 — Phase 1

5. Jun 8, 2026 Clinical update

   AUTO-LT1 — Phase 2

View all clinical trial activity →

• What is Autolus?

  Tubulis is a pharma organization headquartered in Munich, DE. It trades on NYSE under ticker AUTL. Primary therapeutic focus areas include Severe, Refractory Systemic Lupus Erythematosus, Refractory Progressive Multiple Sclerosis, Relapsed or refractory B cell acute lymphoblastic

• Is Autolus publicly traded?

  Yes. Autolus is listed with ticker AUTL on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Autolus develop or market?

  We link 17 drug profile(s) where Autolus is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/autolus-therapeutics-plc#company-drugs.

• What are the latest developments for Autolus?

  In the last 12 months our linked public records show 16 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Autolus focus on?

  Autolus focuses on Severe, Refractory Systemic Lupus Erythematosus, Refractory Progressive Multiple Sclerosis, Relapsed or refractory B cell acute lymphoblastic leukaemia based on our analysis of their pipeline programs and drug development activities.